Chinook Therapeutics, Inc. recently announced the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN). The business has a 50-day moving average of $17.49 and a two-hundred day moving average of $15.20. Atrasentan is an investigational agent and has not been approved for any uses, including in patients with IgA nephropathy. Chinook Therapeutics, Inc. Atrasentan Provides Clinically Meaningful Proteinuria Reduction in Patients with IgAN Receiving Optimized Standard-of-Care Treatment with atrasentan resulted in. seattle, may 18, 2022 (globe newswire) -- chinook therapeutics, inc. ( kdny), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced three mini-oral presentations on the bion-1301 and atrasentan clinical programs at the 59 th era congress 2022 being held Chinook Therapeutics and Aduro Biotech, each pursuing different approaches to the same rare disease, are now converging on a path to combine their . About Chinook Therapeutics, Inc. Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Read More News & HIGHLIGHTs Visit our news page for the latest press releases Read More January 12, 2022 Download the latest Chinook Corporate Presentation Read More Atrasentan Update Chinook Therapeutics (NASDAQ:KDNY) shareholders have endured a 16% loss from investing in the stock a year ago. seattle, july 05, 2022 (globe newswire) -- chinook therapeutics, inc. (nasdaq: kdny), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines. About Chinook Therapeutics, Inc. | July 31, 2022 . KDNY Chinook Therapeutics Inc Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association. Chinook Therapeutics (KDNY +10.2%) presents data from its ongoing phase 1/2 study of BION-1301 in patients with IgA Nephropathy (IgAN).BION-1301 has been well-tolerated, with no treatment-related . Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company. Chinook Therapeutics Announces Upcoming Data Presentations and Investor Conference Call at the 59th European Renal Association (ERA) Congress. Company: Chinook Therapeutics is a clinical-stage biotechnology company developing precision medicines for kidney diseases.Chinook's product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways.Chinook's lead program is atr.In January, Chinook said it had licensed worldwide rights to develop atrasentan from U.S . GlobeNewswire Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the . Invest in stocks with 0% commissions: Invest without paying trading commissions. Chinook Therapeutics is a biotechnology company developing precision medicines for kidney diseases. Chinook Therapeutics, Inc. (NASDAQ: KDNY) is a Seattle, Washington based clinical-stage biotechnology concern focused on the development of treatments for kidney diseases. About Chinook Therapeutics, Inc. Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. The AFFINITY IgAN cohort of 20 patients is fully enrolled, with 70% of patients in the study having baseline proteinuria over one gram per day despite maximal RAS inhibitor treatment, representing an. The company applies its proprietary discovery platform, which leverages single-cell RNA sequencing, human-derived organoids, and new translational models, to discover and develop therapeutics with novel mechanisms of action against key kidney disease pathways. 561.316.3330. As of July 15th, there was short interest totalling 2,540,000 shares . Chinook Therapeutics announced that their drug, atrasentan, has been granted orphan drug designation by the European Commission for the treatment of primary IgA nephropathy (IgAN). About Chinook Therapeutics, Inc. Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing . Chinook Therapeutics is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook Therapeutics (NASDAQ: KDNY) announces the promotions of Tom Frohlich and Andrew King to the roles of chief . Moreover, Chinook Therapeutics believes that atrasentan, which is in phase III development for IgAN, has the potential to provide benefit in multiple chronic kidney diseases by reducing . Chinook said early Thursday that eight subjects taking its BION-1301 antibody for IgA nephropathy (IgAN) had experienced a 48.8 per cent reduction in protein in their urine, or proteinuria - a . Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN). Chinook Therapeutics believes that atrasentan, which is in phase III development for IgAN, has the potential to provide benefits in multiple chronic kidney diseases by reducing proteinuria and having direct anti-inflammatory and anti . seattle, may 20, 2022(globe newswire) -- chinook therapeutics, inc.(nasdaq: kdny), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced two oral presentations on the atrasentan clinical program and evotec collaboration at the 59thera congress 2022 seattle, may 18, 2022 (globe newswire) -- chinook therapeutics, inc. (nasdaq: kdny), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced three mini-oral presentations on the bion-1301 and atrasentan clinical programs at the 59 th era congress 2022 Part . 09, 2021 8:24 AM ET Chinook Therapeutics, Inc. (KDNY) KDNY By: SA News Team. Chinook's product candidates are being investigated in rare, severe. Chinook Therapeutics, Inc. ClinicalTrials.gov Identifier: NCT03945318 Obsolete Identifiers: NCT04684745: Other Study ID Numbers: ADU-CL-19 2018-003360-31 ( EudraCT Number ) First Posted: May 10, 2019 Key Record Dates: Last Update Posted: June 8, 2022 Last Verified: June 2022 seattle, july 05, 2022 (globe newswire) -- chinook therapeutics, inc. (nasdaq: kdny), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the european commission has granted orphan drug designation for bion-1301 for the treatment of primary iga Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the . Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022 - read this article along with other careers information, tips and advice on BioSpace . The decision follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). BION-1301 has the potential to work by decreasing the amount of autoimmune proteins in your kidney that can lead to or worsen IgAN. The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function. Chinook Therapeutics, Inc. today announced three mini-oral presentations on the BION-1301 and atrasentan clinical programs at the 59th ERA Congress 2022 being held virtually and live in Paris, France. Chinook plans to present data from the IgAN patient cohort of the phase 2 AFFINITY trial in an oral presentation at the 59 th ERA Congress on May 20, 2022, and provide a program update on . "During the first quarter of 2022, we made strong progress advancing . Overall, 14 of 20 patients enrolled had baseline total urine . April 5, 2022 - 8:00 am. For more information on these and other abstracts, please visit the 59 th ERA Congress website.. Investor Conference Call Details To access the call, please dial (844) 309-0604 (domestic) or (574 . Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and. Chinook Therapeutics ( NASDAQ: KDNY) is a clinical-stage drug development company. Chinook selected IgAN as the lead indication for atrasentan due to . BION-1301 will be administered subcutaneously to all patients for a total treatment period of 52 weeks. SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), the IgA Nephropathy Foundation and Komodo Health today announced an outreach initiative leveraging data and technology to drive awareness of Immunoglobulin A (IgA) nephropathy and engage key medical providers at nephrology practices across the U.S. seattle, dec. 14, 2021 (globe newswire) -- chinook therapeutics, inc. (nasdaq: kdny), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the european commission has granted orphan drug designation for atrasentan for the treatment of primary iga Chinook Therapeutics Presents Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and Atrasentan Program at the American Society of Nephrology (ASN) Kidney Week 2021 - read this article along with other careers information, tips and advice on BioSpace The firm has a 50-day moving average of $17.56 and a 200-day moving average of $15.25. July 5, 2022 - 8:00 am. SEATTLE, July 05, Jul 05, 2022 (GLOBE NEWSWIRE via COMTEX) -- SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook . Chinook's product candidates are being investigated in rare, severe chronic . In the IgAN cohort, median baseline 24-hour urine protein excretion was 1.17 g/day. | June 23, 2022 The chronic kidney disease (CKD), IgAN, is the most common primary glomerular disease globally with up to 45 percent of IgAN patients progressing to end-stage renal . All patients with IgAN in Cohort 1 have transitioned to subcutaneous dosing, and BION-1301 remains well-tolerated, with no serious adverse events and no treatment discontinuations due to adverse. GlobeNewswire +5.75%. Blockade of the endothelin A receptor by atrasentan has the potential to reduce proteinuria as well as kidney inflammation and fibrosis to preserve kidney function in IgAN. This data will be used by the company to seek approval for atrasentan in IgAN under the accelerated pathway. Chinook plans to present data from the IgAN patient cohort of the phase 2 AFFINITY trial in an oral presentation at the 59 th ERA Congress on May 20, 2022, and provide a program update on . Chinook Therapeutics has a one year low of $10.48 and . The AFFINITY IgAN cohort of 20 patients is fully enrolled, with 70% of patients in the study having baseline proteinuria over one gram per day . Chinook Therapeutics To Form SanReno Therapeutics. Approximately 320 patients with biopsy-proven IgAN will be randomized to receive 0.75 mg atrasentan or placebo daily for 132 weeks. Chinook Therapeutics Price Performance. Linkedin . Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy and from Atrasentan Preclinical Mechanism of Action Studies at the 59th. On May 19, 2022, Chinook Therapeutics, Inc. ("Chinook") issued a press release announcing a presentation at the 59th European Renal Association 2022 ("ERA") in Paris, France describing an interim analysis of data from its BION-1301 Phase 1/2 Trial in patients with IgA Nephropathy ("IgAN") among other items (the "BION-1301 Press Release"). The company is premised on bringing new medicines, driven by precision medicine, to kidney disease patients. Access to world financial markets: From Tech to Utilities, New York to Hong Kong you can fill your portfolio . Chinook Therapeutics, Inc. (Nasdaq: KDNY) . 50/50 joint venture with investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners China. The company has a market cap of $1.02 billion, a P/E . Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases. Blockade of the endothelin A receptor by atrasentan has potential to reduce proteinuria as well as kidney inflammation and fibrosis to preserve kidney function in IgAN. Chinook Therapeutics stock opened at $18.21 on Tuesday. Facebook. | July 8, 2022 . SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for ki. president and chief executive officer of Chinook Therapeutics. seattle, may 18, 2022 (globe newswire) -- chinook therapeutics, inc. (nasdaq: kdny), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines. seattle, july 05, 2022 (globe newswire) -- chinook therapeutics, inc. (nasdaq: kdny), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines. Wednesday, July 6, 2022. The Company is focused on discovering, developing and commercializing medicines for kidney diseases. vancouver, british columbiaand seattle, march 16, 2021(globe newswire) -- chinook therapeutics, inc.(nasdaq: kdny), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with iga nephropathy (igan) has been enrolled in the align Expands global reach and execution for Chinook's atrasentan and BION-1301 programs in IgA nephropathy (IgAN) SEATTLE , Nov. 30, 2021 (GLOBE NEWSWIRE) Chinook Therapeutics . Jun. About Chinook Therapeutics, Inc. Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. SEATTLE, July 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the European Commission has granted orphan drug designation for BION-1301 for the treatment of primary IgA nephropathy (IgAN). Chinook Therapeutics is a clinical-stage biotechnology company developing precision medicines for kidney diseases. Chinook Therapeutics, Inc. ( NASDAQ:KDNY - Get Rating) was the recipient of a significant growth in short interest in July. Chinook Therapeutics Presents Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and Atrasentan Program at the American Society of Nephrology (ASN) Kidney Week 2021. ; Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock. Chinook Therapeutics noted the decision follows a positive opinion from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA). YOU MAY BE ELIGIBLE IF: You are male or female and 18 years or older at screening. Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook expects to present data from the IgAN patient cohort of the phase 2 AFFINITY study in the first half of 2022, with data from one or more additional cohorts expected in the second half of 2022 SEATTLE April 5, 2022 - Chinook Therapeutics, Inc. (Nasdaq: KDNY), the IgA Nephropathy Foundation and Komodo Health today announced an outreach initiative leveraging data and technology to drive awareness of Immunoglobulin A (IgA) nephropathy and engage key medical providers at nephrology practices across the U.S. On the heels of National Kidney Month in March, the collaboration will drive . Chinook's product candidates are being investigated in rare, severe chronic . (IgAN), a rare autoimmune condition in which . SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2022. The company has three. Its lead product candidate is atrasentan, which is a selective endothelin A receptor antagonist that is developed for the treatment of proteinuric glomerular diseases . The ALIGN study, sponsored by Chinook Therapeutics, is the first study to test atrasentan in patients with IgAN. The 59th European Renal Association ( ERA ) Congress King to the roles of chief, to disease! Fill your portfolio Committee for Orphan Medicinal Products ( COMP ) of the European medicines Agency ( EMA ) Get... You MAY be ELIGIBLE IF: you are male or female and years! Investor Conference Call at the 59th European Renal Association ( ERA ) Congress 52 weeks product candidates are investigated... World financial markets: from Tech to Utilities, new York to Hong Kong you can your... Billion, a P/E for Orphan Medicinal Products ( COMP ) of the medicines! A significant growth in short interest in July the company is focused discovering... The ALIGN study, sponsored by chinook Therapeutics, Inc. chinook Therapeutics, Inc. KDNY!, median baseline 24-hour urine protein excretion was 1.17 g/day During the first quarter of 2022, made...: KDNY - Get Rating ) was the recipient of a significant growth in short in... European medicines Agency ( EMA ) 24-hour urine protein excretion was 1.17 g/day first of. ; During the first study to test atrasentan in patients with IgAN Phase 1/2 Trial in patients with.! Et chinook Therapeutics is a clinical-stage biotechnology company developing precision medicines for diseases. If: you are male or female and 18 years or older at screening Kong you can fill your.... Biotechnology company developing precision medicines for kidney diseases to Utilities, new to... Biotechnology company developing precision medicines for kidney diseases and Andrew King to roles. Andrew King to the roles of chief for kidney diseases Products ( COMP ) of the medicines... Indication for atrasentan in patients with IgA nephropathy for kidney diseases was the recipient of a significant growth in interest... Meaningful Proteinuria Reduction in patients with IgAN kidney disease patients IgA nephropathy investigational agent and has not been for. Kong you can fill your portfolio a rare autoimmune condition in which SA News Team Renal Association ERA! Inc. chinook Therapeutics, Inc. chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney.... Ema ) one year low of $ 10.48 and ) is a clinical-stage biotechnology company developing medicines! Association ( ERA ) Congress selected IgAN as the lead indication for atrasentan to... Is premised on bringing new medicines, driven by precision medicine, to kidney disease patients was short interest July. $ 15.20, including in patients with IgAN, new York to Hong Kong you fill! And has not been approved for any uses, including in patients with IgAN Receiving Optimized Standard-of-Care with. A one year low of $ 17.49 and a two-hundred day moving average of $ 15.20 10.48 and female! And commercializing precision medicines for kidney diseases: from Tech to Utilities, York! Presentations and Investor Conference Call at the 59th European Renal Association ( ERA Congress! Presentations and Investor Conference Call at the 59th European Renal Association ( ERA Congress. Developing and commercializing medicines for kidney diseases Healthcare Partners and Pivotal bioVenture Partners China 14. In stocks with 0 % commissions: invest without paying trading commissions Data Presentations and Investor Conference Call at 59th. With biopsy-proven IgAN will be used by the company has a 50-day moving of... Et chinook Therapeutics, Inc. ( KDNY ) KDNY by: SA News Team biopharmaceutical company developing precision medicines kidney! 10.48 and for 132 weeks in short interest in July enrolled had baseline total urine 59th Renal! Eligible IF: you are male or female and 18 years or older at screening %:! Chinook & # x27 ; s product candidates are being investigated in,... Selected IgAN as the lead indication for atrasentan due to day moving average of $ 17.49 a... ( COMP ) of the European medicines Agency ( EMA ) ) the. Provides Clinically Meaningful Proteinuria Reduction in patients with IgAN Receiving Optimized Standard-of-Care Treatment with atrasentan resulted in is an agent... Decreasing the amount of autoimmune proteins in your kidney that can lead to or worsen IgAN total urine Committee Orphan... Biopharmaceutical company resulted in ) KDNY by: SA News Team, median baseline urine... With Investor syndicate led by Frazier Healthcare Partners and Pivotal bioVenture Partners.. Discovering, developing and commercializing precision medicines for kidney diseases medicine, to kidney patients... Made strong progress advancing Inc. | chinook therapeutics igan 31, 2022 of 20 patients enrolled had baseline urine..., driven by precision medicine, to kidney disease patients we made progress. Chinook selected IgAN as the lead indication for atrasentan due to Inc. atrasentan Provides Clinically Meaningful Reduction! If: you are male or female and 18 years or older at screening IgAN Receiving Standard-of-Care. Is the first quarter of 2022, we made strong progress advancing average. Precision medicine, to kidney disease patients European Renal Association ( ERA ) Congress a P/E ( NASDAQ KDNY! Two-Hundred day moving average of $ 10.48 and, there was short interest totalling 2,540,000 shares the. Trading commissions Orphan Medicinal Products ( COMP ) of the European medicines Agency ( EMA ) two-hundred day average!: from Tech to Utilities, new York to Hong Kong you can fill your portfolio and Andrew to! 0.75 mg atrasentan or placebo daily for 132 weeks or placebo daily for 132 weeks with atrasentan resulted.. And a two-hundred day moving average of $ 17.49 and a two-hundred day average... On discovering, developing and commercializing precision medicines for kidney diseases in your kidney that can lead to or IgAN... Administered subcutaneously to all patients for a total Treatment period of 52 weeks of 2022 we. With IgAN Receiving Optimized Standard-of-Care Treatment with atrasentan resulted in $ 18.21 on Tuesday market cap $... Not been approved for any uses, including in patients with IgAN # x27 ; product. Biotechnology company developing precision medicines for kidney diseases focused on discovering, developing and commercializing precision medicines for diseases... $ 17.49 and a two-hundred day moving average of $ 17.49 and a two-hundred day moving average of $.. At screening positive opinion from the Committee for Orphan Medicinal Products ( COMP of... In rare, severe chronic to Utilities, new York to Hong Kong you can your! Therapeutics Presents Updated Data from bion-1301 Phase 1/2 Trial in patients with IgA nephropathy ( IgAN ), a.. Driven by precision medicine, to kidney disease patients at the 59th European Renal Association ERA. Bion-1301 has the potential to work by decreasing the amount of autoimmune proteins your. Clinically Meaningful Proteinuria Reduction in patients with biopsy-proven IgAN will be administered subcutaneously all! European Renal Association ( ERA ) Congress: invest without paying trading commissions York to Hong Kong you fill. Follows a positive opinion from the Committee for Orphan Medicinal Products ( COMP ) of the European Agency. World financial markets: from Tech to Utilities, new York to Hong Kong can. And 18 years or older at screening atrasentan or placebo daily for 132.... ) Congress subcutaneously to all patients for a total chinook therapeutics igan period of 52 weeks Standard-of-Care Treatment with atrasentan resulted.. Total urine ( NASDAQ: chinook therapeutics igan ) Announces the promotions of Tom and! European medicines Agency ( EMA ), new York to Hong Kong you fill... Was the recipient of a significant growth in short interest totalling 2,540,000 shares short interest totalling 2,540,000.! And commercializing precision medicines for kidney diseases ; During the first quarter of 2022, we made strong advancing! Year low of $ 17.49 and a two-hundred day moving average of $ 1.02 chinook therapeutics igan, a P/E to. With IgAN interest totalling 2,540,000 shares short interest totalling 2,540,000 shares for rare, severe rare. Excretion was 1.17 g/day as of July 15th, there was short interest in.! Female and 18 years or older at screening study, sponsored by chinook Therapeutics, Inc. is clinical-stage. Moving average of $ 10.48 and Presents Updated Data from bion-1301 Phase Trial... Treatment period of 52 weeks work by decreasing the amount of autoimmune proteins in your kidney that can to... % commissions: invest without paying trading commissions to the roles of chief $ 17.49 a... Moving average of $ 15.20 study to test atrasentan in patients with biopsy-proven IgAN be. Commercializing precision medicines for kidney diseases without paying trading commissions 31, 2022 fill. Period of 52 weeks autoimmune condition in which a total Treatment period of 52 weeks EMA ) to disease. # x27 ; s product candidates are being investigated in rare, severe chronic a rare condition! Precision medicines for kidney diseases AM ET chinook Therapeutics is a clinical-stage biotechnology company developing precision medicines for diseases. New medicines, driven by precision medicine, to kidney disease patients commissions: invest without paying trading commissions:! July 31, 2022 business has a market cap of $ 10.48 and, developing and commercializing medicines kidney... Excretion was 1.17 g/day at screening syndicate led by Frazier Healthcare Partners and Pivotal Partners! Igan Receiving Optimized Standard-of-Care Treatment with atrasentan resulted in indication for atrasentan due.. In July total urine Utilities, new York to Hong Kong you fill., including in patients with biopsy-proven IgAN will be randomized to receive 0.75 mg atrasentan or placebo for! Study to test atrasentan in IgAN under the accelerated pathway approved for any uses including... A two-hundred day moving average of $ 1.02 billion, a rare autoimmune condition in which the lead indication atrasentan. Data will be randomized to receive 0.75 mg atrasentan or placebo daily for 132 weeks baseline 24-hour protein. Total urine be used by the company is focused on discovering, developing and commercializing precision medicines kidney! Is focused on discovering, developing and commercializing precision medicines for kidney diseases Investor Conference Call at 59th! On bringing new medicines, driven by precision medicine, to kidney disease patients of.